| AMR | antimicrobial resistance |
| AMC | amoxicillin–clavulanic acid |
| AMK | amikacin |
| AMX | amoxicillin |
| AST | antimicrobial susceptibility testing |
| BSI | bloodstream infections |
| CAZ | ceftazidime |
| CDC | Centers for Disease Control and Prevention |
| CIP | ciprofloxacin |
| CTX | cefotaxime |
| COL | colistin |
| EUCAST | European Committee on Antimicrobial Susceptibility Testing |
| ESBLs | extended-spectrum β-lactamases |
| ETP | ertapenem |
| FEP | cefepime |
| FOS | fosfomycin |
| FOX | cefoxitin |
| GEN | gentamicin |
| GNBs | Gram-negative bacteria |
| IAI | intra-abdominal infections |
| IMP | imipenem |
| IQC | internal quality control |
| LART | L’AntibioRésistance en Tunisie |
| MEM | meropenem |
| MDR | multidrug-resistant |
| NAL | nalidixic acid |
| PIP | piperacillin |
| RTIs | respiratory tract infections |
| SXT | trimethoprim–sulfamethoxazole |
| TIC | ticarcillin |
| TIM | ticarcillin–clavulanic acid |
| TZP | piperacillin-tazobactam |
| UTIs | urinary tract infections |
| 3GCs | 3rd-generation cephalosporins |